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Increased expression of angiogenic growth factors
in age-related maculopathy
Mike KliVen, Hari S Sharma, Cornelia M Mooy, Sonja Kerkvliet, Paulus T V M de Jong
Abstract
Aims/background—The late stages of age-
related maculopathy (ARM), especially
neovascular macular degeneration
(ARMD), can severely aVect central vision
and are the main cause of blindness in the
elderly in the Western world. It has been
shown that angiogenic growth factors are
present in neovascular membranes in
ARMD. However, it is not known if
angiogenic growth factors play a role in
the onset of neovascularisation.
Methods—In order to elucidate the in-
volvement of angiogenic growth factors in
the initiation of neovascularisation in
early stages of ARM, the expression
patterns of VEGF, TGF-â, b-FGF, and
PDGF-AA on 18 human maculae with
ARM, and on 11 control specimens were
investigated immunohistochemically.
Results—A significantly increased expres-
sion of VEGF (p=0.00001) and TGF-â
(p=0.019) was found in the retinal pigment
epithelium (RPE) of maculae with ARM
compared with control maculae. Further-
more, an increased expression of VEGF
and PDGF was found in the outer nuclear
layer of maculae with ARM.
Conclusion—These results demonstrate
an increased expression of VEGF in the
RPE, and in the outer nuclear layer in
maculae with ARM, that could be involved
in the pathogenesis of neovascular macu-
lar degeneration. Furthermore, enhanced
TGF-â expression in the RPE cells of
maculae with early stages of ARM was
shown.
(Br J Ophthalmol 1997;81:154–162)
Age-related maculopathy (ARM) is a disorder
of the macular area of the eye. Many
histopathological changes—for example,
drusen and basal laminar deposit (BLD) can
be seen in early types of ARM.1 2 The late
stages of ARM are nowadays called age-related
macular degeneration (ARMD) and are subdi-
vided into dry ARMD (geographic atrophy),
and wet ARMD (neovascular ARMD).3
ARMD is the main cause of blindness in the
elderly population in the Western world. In the
Netherlands the prevalence of neovascular
ARMD is twice as high as dry ARMD,4
whereas there is an equal distribution between
the two in the USA.5 During neovascular
ARMD, the subretinal pigment epithelial
(RPE) space is invaded by growing new blood
vessels (angiogenesis) sprouting from the
underlying choriocapillaris.1 2 6 7 These neovas-
cular blood vessels can cause haemorrhages,
leading to the formation of a disciform scar
with rapid visual impairment. Despite several
studies on the morphology of ARM, the
molecular mechanisms and factors contribut-
ing to the pathogenesis of neovascular ARMD
remain to be characterised.
Angiogenesis, being a complex phenomenon
comprising several distinct processes that
include endothelial cell migration and prolif-
eration, extracellular proteolysis, and vessel
wall remodelling, has been implicated in many
pathophysiological processes. Several growth
factors have been shown to contribute to the
molecular events involved in the regulation of
blood vessel growth.8 9 Likewise, it is assumed
that angiogenic growth factors such as vascular
endothelial growth factor (VEGF), transform-
ing growth factor â (TGF-â), basic fibroblast
growth factor (b-FGF), and platelet derived
growth factor (PDGF) could play an impor-
tant role in the pathogenesis of neovascular
ARMD.
VEGF, also referred to as vascular perme-
ability factor or vasculotrophin, is a heparin
binding peptide mitogen with narrow target
cell specificity, apparently limited to endothe-
lial cells derived from small and large blood
vessels. It promotes vascular permeability and
angiogenesis in vivo.9 TGF-â is a cytokine that
has been implicated in cell proliferation, angio-
genesis, and deposition of extracellular ma-
trix.10 Another angiogenic heparin binding
growth factor, b-FGF, has been suggested to
contribute to the process of ocular
neovascularisation.11–13 PDGF is highly chemo-
tactic to the RPE cells,14 and is known to
induce intraocular vascular proliferation.15
Cultured RPE cells have been shown to
produce all the above mentioned growth
factors.16–20
Recently, increased levels of VEGF, b-FGF,
and TGF-â in surgically removed neovascular
membranes from eyes with neovascular
ARMD have been demonstrated.11 13 21 How-
ever, it is not yet established whether these
growth factors play a role in the initiation of the
process or they are secondary to the new blood
vessel formation. The purpose of this study was
to investigate the possible presence of ang-
iogenic growth factors (VEGF, TGF-â,
b-FGF, and PDGF-AA) in the early stages of
ARM—that is, before the onset of neovascu-
larisation.
Materials and methods
PREPARATION OF HUMAN MACULAR TISSUE
We used 29 human eye bank eyes from 25 sub-
jects aged between 38 and 96 years (mean age
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78 years), with postmortem time from 1 to 11
hours (mean 7 hours). The donors had no his-
tory of eye disease, and the samples were mac-
roscopically and microscopically checked for
retinal diseases that might stimulate
angiogenesis—for example, diabetic retino-
pathy. The macular area (about 1 cm2) was dis-
sected from the ocular tissue, fixed in phos-
phate buVered formaldehyde (4% v/v, pH 7.4),
and embedded in paraYn for histopathological
classification and immunohistochemistry.
HISTOPATHOLOGICAL CLASSIFICATION OF HUMAN
MACULAR TISSUE
Serial paraYn sections (5 µm) of half the
maculae were made. At regular intervals (three
depths) these were stained with haematoxylin
and eosin, the periodic acid SchiV reaction,
and Mallory staining. The maculae were histo-
logically classified according to their gradation
of drusen and BLD.Drusen and BLD are both
extracellular deposits accumulating in ARM.
Drusen are located external to the basement
membrane of the RPE—that is, within Bruch’s
membrane. BLD is located between the basal
cell membrane and the basement membrane of
the RPE—that is, outside Bruch’s membrane.
Large drusen and BLD (and the chemical
composition of these deposits) are assumed to
be important determinants in the pathogenesis
of ARM.22–27 (For the classification of drusen
and BLD see van der Schaft et al.28) In brief the
classification is: no BLD (class 0); small
solitary patches of BLD (class 1); a thin
continuous layer of BLD (class 2); a thick layer
of BLD of at least half the height of the RPE
cells (class 3); no drusen (class 0); 1 to 3
drusen (class 1); 4 to 10 drusen (class 2); many
or confluent drusen (class 3).28
Since no important changes in histology of
the maculae are present in maculae with both
BLD class 0 or class 1 and drusen class 0 or
class 1, these eyes were categorised as control
samples. All other maculae were classified as
samples with ARM. Two maculae with estab-
lished neovascular ARMD were also included
for examination of growth factor expression.
IMMUNOHISTOCHEMISTRY
ParaYn sections (5 µm) of all maculae were
mounted on 3-amino-propyl-trioxysilane
(Sigma, St Louis, MO, USA) coated glass
slides. After deparaYnisation and rehydration
they were rinsed with water and phosphate
buVered saline. The slides were placed in a
Sequenza Immunostaining Workstation (Shan-
don Scientific Ltd, Astmoor, Runcorn), and
incubated for 20 minutes with normal goat
serum. After this blocking step, slides were
incubated for 30 minutes with either a rabbit
polyclonal antibody directed against VEGF
(Santa Cruz Biotechnology, Santa Cruz, CA,
USA),29 TGF-â (R&D Systems Europe,
Abingdon),11, b-FGF (Serotec, Kidlington,
Oxford),30 or PDGF-AA (Genzyme, Cam-
bridge, MA, USA).31 These antibodies were
characterised as described by the suppliers and
in the literature and were used at a dilution of
1:100, 1:1500, 1:400, and 1:150, respectively.
The anti-TGF-â polyclonal antibody was
panspecific to the several subtypes of TGF-â.
After washing with phosphate buVered saline,
the slides were incubated for 30 minutes with
biotinylated secondary antibodies (Multilink,
1:75 dilution, Biogenex, San Ramon, MO,
USA). The slides were washed again and incu-
bated for 30 minutes with alkaline phosphatase
conjugated streptavidin (Biogenex, San
Ramon, MO, USA, dilution 1:50). Finally, the
slides were rinsed with 0.2 M TRIS–HCl pH
8.0, and stained for 30 minutes with 0.3%New
Fuchsin/TRIS–HCl (Sigma, St Louis, MO,
USA). The sections were counterstained with
Mayer’s haematoxylin for 15 seconds, rinsed
for 10 minutes with water, and air dried. Before
the incubation with anti-TGF-â and anti-b-
FGF antibodies, the sections were treated with
5 µg/ml saponin for 30 minutes at room
temperature, and with 5.5 mU/ml pronase E
(Sigma, St Louis, MO, USA) for 7 minutes at
37˚C, respectively.
In negative controls, the primary antibodies
were replaced by normal rabbit serum (Dako,
Glostrup, Denmark, dilution 1:10). As a
second negative control for VEGF immunos-
taining, the anti-VEGF antibodies were
blocked with the VEGF peptide (Santa Cruz
Biotechnology) before the incubation of the
tissue. We did not perform peptide blocking
with the other antibodies, because the most
important findings in this study concern
VEGF. Furthermore, the anti-TGF-â antibody
is panspecific and the two other antibodies
have been described in the literature.11 30 31
Blood vessels were used as internal positive
controls for anti-VEGF and anti-PDGF anti-
bodies. Nerve fibres were used as internal posi-
tive controls for TGF-â and b-FGF immuno-
staining. Growth factor expression was
semiquantified on the basis of percentage of
positively stained tissue, and to a lesser extent
the intensity of tissue staining: − = no staining;
+/− = faint staining in less than 50% of the tis-
sue; + = positive staining in less than 50% of
the tissue; ++ = positive staining in more than
50% of the tissue. Sections were scored twice
(by the first and third author) with a 3 week
interval. Intraobserver variability was negligi-
ble. Interobserver variability was only observed
between +/− and + scores in some cases. These
cases were scored after mutual consultation. In
our opinion, these four gradation groups are
readily discriminated, especially because posi-
tive staining occurred either in less than 33% of
the tissue or in more than 66% of the tissue.
We have chosen to leave out the 33% to 66%
group in our gradation system for simplifica-
tion since none of the specimens had a positive
staining percentage between 33% and 66%.
STATISTICAL ANALYSIS
To compare the protein expression of VEGF,
TGF-â, b-FGF, and PDGF between ARM
maculae and controls, we have used the
Mann–Whitney U test, because this is one of
the few non-parametric statistics that has a
useful interpretation. The diVerence of the
individual growth factor expression between
ARM and control maculae was assumed to
be statistically significant if p<0.05. Because
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photoreceptors and inner retinae were not
present in 12 specimens (a common problem
with postmortem human eyes), p values could
not be computed for these tissue layers.
Results
HISTOPATHOLOGICAL CLASSIFICATION OF HUMAN
MACULAR TISSUE
Eleven maculae were classified as controls,
nine maculae had neither BLD nor drusen, one
macula had BLD class 1, and one macula had
BLD class 1 and drusen class 1 (Table 1). Six-
teen specimens were classified as maculae with
ARM; six maculae had only BLD (class 2 or
3), 1 macula had only drusen (class 3), and
nine maculae had both BLD (class 2 or 3) and
drusen (class 2 or 3) (Table 1). Two maculae
had neovascular ARMD (Table 1). The diVer-
ence of mean age between controls (73 years)
and ARM eyes (81 years) was not statistically
significant (Student’s t test, p>0.1).
IMMUNOLOCALISATION OF VEGF
Immunohistochemically, VEGF was localised
in the smooth muscle cells of the blood vessels
of the choroid and in some of the RPE cells in
control maculae (Fig 1A). A significant in-
crease in VEGF expression was found in the
RPE cells (p = 0.00001) and choroidal blood
vessels (p = 0.0064) of human maculae with
early ARM and maculae with neovascular
ARMD compared with controls (Fig 1B). Fur-
thermore, the outer nuclear layer of human
maculae with ARM and neovascular ARMD
showed more VEGF immunoreactivity (Fig
1C) than those of control maculae. VEGF
expression was also found in BLD (nine out of
17 maculae) (Fig 1C). Except for one large
calcified drusen that showed positive staining
for VEGF (Fig 1D), none of the drusen
stained. Additionally, strong positive staining
for VEGF was found in macrophages infiltrat-
ing through Bruch’s membrane (Fig 1E). In
negative controls, no staining was seen at all.
IMMUNOLOCALISATION OF TGF-â
TGF-â was scarcely localised in some of the
RPE cells, and in the walls of blood vessels
(smooth muscle cells as well as endothelial
cells) in the choroid of control human maculae
(Fig 2A). A significantly increased expression
of TGF-â was found in the RPE of human
maculae with early ARM, and in maculae with
neovascular ARMD compared with control
specimens (p = 0.019). The expression in the
choroid was the same in both groups. BLD
stained with antibodies directed against
TGF-â in eight out of 17 maculae (Fig 2B).
These were the same maculae that showed
expression of VEGF in BLD. None of the
drusen stained with the anti-TGF-â antibody
(Fig 2B).
IMMUNOLOCALISATION OF B-FGF
Antibodies directed against b-FGF showed
expression of this growth factor in all RPE cells
and in the blood vessels of the choroid in con-
trol human maculae. A significantly decreased
expression of b-FGF was found in the choroi-
dal blood vessels of ARM maculae (p =
0.0005), but no diVerence in expression was
found in the RPE or in the photoreceptors.
The distribution of b-FGF in ARM maculae is
reflected in Figure 2C. BLD stained weakly
with anti-b-FGF antibodies in nine out of 17
maculae; seven of these also stained with anti-
VEGF and anti-TGF-â antibodies. The extra-
cellular matrix surrounding the macrophages
infiltrating through Bruch’s membrane also
stained weakly positive for b-FGF. None of the
drusen stained with the anti-b-FGF antibody.
IMMUNOLOCALISATION OF PDGF-AA
In control maculae PDGF was only localised in
the smooth muscle cells of the blood vessels.
The outer nuclear layer in three maculae with
early stages of ARM, and both maculae with
neovascular ARMD stained strongly, whereas
the inner nuclear layer, and ganglion cell layer
stained positive as well (Fig 2D). None of the
control specimens showed positive staining in
the retinal layers. Some RPE cells stained
weakly in six maculae with ARM and in four
controls. BLD did not express PDGF. One
large drusen involved in the edge of a
neovascular membrane showed positive stain-
ing for PDGF-AA (Fig 2E). All other drusen
were negative.
The diVerences of growth factor expression,
in the RPE and choroid, between ARM macu-
lae and controls are visualised in Figure 3. The
statistical analysis was performed on these
data.
Discussion
We have demonstrated a significantly increased
expression of VEGF and TGF-â in RPE cells
of human maculae with early stages of ARM
compared with those of control specimens.
Table 1 Classification of human maculae







1 64 10 0 3 ARM
2 86 10 2 0 ARM
3 88 8 2 0 ARM
4 67 8 2 0 ARM
5 85 4.5 2 1 ARM
6 67 11 2 1 ARM
7 81 7 2 2 ARM
8 87 5 2 2 ARM
9 65 8 2 3 ARM
10 94 10 3 0 ARM
11 74 8 3 0 ARM
12 74 8 3 0 ARM
13 81 7 3 1 ARM
14 86 5 3 2 ARM
15 96 2 3 3 ARM
16 93 4.5 3 3 ARM
17 91 8 3 2 ARM†
18 87 11 3 3 ARM†
19 76 7 0 0 Control
20 55 7 0 0 Control
21 38 9.5 0 0 Control
22 91 4.5 0 0 Control
23 81 5.5 0 0 Control
24 80 9.5 0 0 Control
25 45 8.5 0 0 Control
26 77 9 0 0 Control
27 77 9 0 0 Control
28 87 1 0 1 Control
29 91 8 1 1 Control
PM = postmortem time in hours; BLD = basal laminar deposit;
ARM = age-related maculopathy; *Classification based on the
gradation of BLD and drusen (see materials and methods);
†Neovascular ARMD.
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The blood vessels in the choroid also showed a
significantly increased expression of VEGF in
ARM maculae. No diVerences in RPE staining
of ARM maculae compared with controls were
found with anti-b-FGF, and anti-PDGF anti-
bodies. About 50% of the human maculae with
early ARM showed VEGF, TGF-â, and
b-FGF staining in BLD. Localisation of these
angiogenic growth factors in the BLD, which
deposit is correlated with the development of
neovascular ARMD, points towards their
involvement in the pathogenesis of subretinal
Figure 1 Light microscopic images of immunohistochemistry with anti-VEGF antibodies. (A) Typical example of VEGF
expression in a control macula; VEGF is present in smooth muscle cells (short arrow) of choroidal blood vessels (C) and in
some (long arrows) of the retinal pigment epithelial cells (rpe). (B) The expression of VEGF in the RPE is increased in
ARM maculae in comparison with control maculae. (C) The outer nuclear layer (ONL) and basal laminar deposit (long
arrows) show expression of VEGF in this macula with neovascular macular degeneration. The myofibroblast cells (small
arrows) in the scar tissue (S) contain VEGF as well. (D) Expression of VEGF in a large drusen (D) with calcified bodies
(open arrow) in an ARM macula. (E) Macrophages (long arrow) that have infiltrated Bruch’s membrane (b) in a ARM
macula show intense staining for VEGF.A monocyte (open arrow) shows VEGF expression as well. Original
magnification × 400.
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Figure 2 Light microscopic images of immunohistochemistry with anti-TGF-â (A and B), b-FGF (C), and PDGF-AA
(D and E) antibodies. (A) Control maculae show TGF-â expression in smooth muscle cells (long arrow) and endothelial
cells (short arrow) of choroidal blood vessels (C). The RPE shows only faint staining in most of the control maculae. (B)
TGF-â expression is increased in the RPE of this typical ARM macula. Basal laminar deposit (long arrow) contains
TGF-â as well. Note that the most prominent RPE staining is present on top of a drusen (open arrow) that itself shows no
staining. (C) A typical example of an ARM macula that shows b-FGF expression in the RPE. (D) PDGF-AA expression
in a macula with neovascular macular degeneration. The retina demonstrates PDGF-AA expression, whereas the retina in
control maculae shows no staining at all. Note that the expression in the outer nuclear layer (ONL) is more prominent than
in the inner nuclear layer (INL) and ganglion cell layer (G). (E) PDGF expression in a large drusen (D) in a macula
with neovascular macular degeneration. S = scar tissue, b = Bruch’s membrane. Original magnification × 400.
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neovascularisation. Since the postmortem
times of controls and ARM cases were the
same (mean 7 hours; t test, p = 0.7) the diVer-
ences between controls and cases cannot be
caused by diVerences in postmortem times.
Expression of VEGF in many cell types, in
vivo as well as in vitro, is strongly induced by a
number of factors including hypoxia and
ischaemia.32–35 Recently, it has been shown that
human RPE cells in culture synthesise and
secrete VEGF,20 and that VEGF RNA levels
are increased under hypoxic circumstances.36
Atrophy of the choriocapillaris and atheroscle-
rosis resulting in relative ischaemia of the outer
retina are assumed to be involved in the devel-
opment of neovascular ARMD.2 37–39 In our
study we found higher levels of VEGF in the
RPE and choroid, as well as in the outer
nuclear layer of maculae with ARM. Further-
more, the inner nuclear layer of the retina
showed faint staining as well. In contrast,
Miller et al found an increase of VEGF expres-
sion in the inner nuclear layer, but not in the
outer nuclear layer of ischaemic retina, in a
Figure 3 Comparison of the immunohistochemical expression of VEGF (A and B), TGF-â (C and D), b-FGF (E and
F), and PDGF-AA (G and H) in RPE (A, C, E,G) and choroid (B,D, F,H) between control maculae and ARM
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primate model for retinal neovascularisation.33
This diVerence could be attributed to the two
separate vascular beds supplying the retina
with oxygen and nutrients. A retinal capillary
network that supplies the inner nuclear layer,
and ganglion cell layer, and a network of
extraretinal capillaries in the choroid supplying
the RPE and the outer nuclear layer. The
former is involved in diabetic retinopathy,
which has been studied by Miller et al.33 The
latter is involved in neovascular ARMD.1 2
These results indicate that the diVerentially
increased VEGF staining in the outer and
inner retinal layers in neovascular ARMD and
in proliferative diabetic retinopathy, respec-
tively, could be due to ischaemia caused by
insuYciency of either of the capillary beds.
Furthermore, recent findings of Pe’er et al sup-
port the contention of diVerential expression of
VEGF in the retina as they demonstrated spa-
tial localisation of VEGF mRNA in retinae of
several other ischaemic retinal disorders.40
Other studies reported no VEGF staining in
the RPE cells of normal young individuals/
animals.21 33 40 The weak staining of the RPE
cells in our (older) control specimens could
therefore be the result of an age-related
increase in VEGF levels. Consequently, a small
age-related component of the increased VEGF
immunoreactivity in RPE cells from ARM
cases can not be excluded.
As can be seen from Figure 3 more than half
of the eyes with ARM showmarkedly increased
VEGF staining (++) in the retinal pigment
epithelium. None of the control eyes showed
such staining. It is known that the evolution of
early ARM to neovascular macular degenera-
tion shows a lot of variation and the causal
relation between the subsequent stages of
ARM has not been established. In fact, it is
known that not all eyes with early ARM
progress to neovascular ARMD. However, it
could well be that it is just a matter of time for
neovascularisation to develop. On the other
hand one could think of other factors (angio-
genesis inhibitors) that are known to be
produced by the retina that slow down this
process.41 Therefore, we think it is valid to
speculate that the increased expression of
VEGF in ARMmaculae could be one factor in
a multifactorial development of neovascular
macular degeneration.
In the present study, we demonstrated an
intense expression of VEGF in infiltrating
macrophages in ARM. The infiltration of mac-
rophages through Bruch’s membrane has been
assumed to be involved in the process of
neovascularisation in ARM.42–44 This migration
could well be promoted by the increased levels
of VEGF in maculae with ARM.45
TGF-â is an indirect angiogenic growth fac-
tor that stimulates angiogenesis by inducing
the production of other angiogenic factors like
VEGF.46 TGF-â plays an important role in the
formation of extracellular matrix.10 It increases
the production of matrix molecules and inhib-
its matrix degradation through stimulation of
protease inhibitor synthesis, and inhibiting the
synthesis of proteases.10 We demonstrated a
significantly increased expression of TGF-â in
the RPE cells of maculae with early stages of
ARM, strongly suggesting that TGF-â could
be involved in the accumulation of extracellu-
lar deposits such as BLD and drusen. BLD
contains many extracellular matrix molecules
such as collagen type IV, laminin, glycos-
aminoglycans, and several other carbohydrate
structures.47–49 Furthermore, TGF-â is highly
chemotactic to monocytes.50 The increased
expression of this growth factor in the RPE
cells of early ARMmaculae could contribute to
the infiltration of macrophages through
Bruch’s membrane.
Basic FGF has been reported to be able to
rescue photoreceptors from degeneration.51 52
Although we have demonstrated b-FGF ex-
pression in the RPE, we could not demonstrate
higher levels of this growth factor in the RPE
cells of maculae with early stages of ARM or
with neovascular ARMD (and subsequent
degeneration of photoreceptors) compared
with control specimens. Therefore, we can
confirm the results of two recent papers, dem-
onstrating expression of b-FGF in RPE cells
involved in surgically removed neovascular
membranes,11 13 but we cannot point to a
pathogenic role of b-FGF in the early stages of
ARM. Furthermore, we have found a signifi-
cantly decreased expression of b-FGF in the
choroidal blood vessels in maculae with early
stages of ARM compared with control macu-
lae, indicating that b-FGF may not be contrib-
uting to early stages of ARM where other
potent angiogenic factors like VEGF act as
endothelial cell mitogen.
We demonstrated an increased expression of
PDGF in the outer nuclear layer of three out of
17 maculae with early ARM, and in all macu-
lae with neovascular ARMD, whereas none of
the control maculae showed expression of
PDGF in this layer. However, not all speci-
mens contained all retinal layers, so it seemed
unwise to perform statistical analysis on the
staining characteristics of the retinal layers in
this study. Similar to the results of Reddy et al,
we did not see expression of PDGF in the RPE
cells.13 Since PDGF is highly growth promot-
ing and chemotactic to the RPE cells,14 the
increased expression of PDGF in the outer
nuclear layer could be attributed to its partici-
pation in the migration of RPE cells towards
the inner retina, often seen during ARMD.
In conclusion, we have demonstrated that
increased staining of a number of angiogenic
growth factors can be observed in the early
stages of ARM. Therefore, they may be
involved in the early pathogenesis of neovascu-
lar ARMD. The increased levels of VEGF in
RPE cells, and the outer nuclear layer of macu-
lae with ARM might be caused by a relative
hypoxia of the outer retina. Increased TGF-â
expression in the RPE cells of maculae with
early stages of ARM could, in addition to its
indirect angiogenic role (for example, stimulat-
ing the production of angiogenic growth factors
like VEGF), induce the accumulation of extra-
cellular deposits such as BLD and drusen. It is
imperative to emphasise here that a specific
inhibition of VEGF can prevent neovascularisa-
tion in a mouse model of ischaemia induced
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retinal neovascularisation.53 Therefore, it might
be speculated that the identification of changes
in VEGF levels in human maculae with ARM
can provide us with a molecular target for
antiangiogenic therapies in treating neovascu-
lar ARMD.54
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thereof, donated for transplantation purposes, which could not
be used for implantation in a patient. We thank the donor and
his family for their generosity and we thank the BIS foundation
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Ophthalmic Research Institute (Amsterdam, Netherlands) for
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